Role of IL-18 and caspas-9 polymorphism in disease susceptibility in prostate cancer


Backgrounds: Prostate cancer (PCa) is the 2nd utmost global prevalent male cancer and major cancer in economically developed countries. Environmental factors and person having genetic polymorphism might have a function in prediction and consequently treatment strategies for a particular disease in a particular or a group of patients. This emerging approach has the potential to improve prediction of susceptibility to prostate cancer and disease progression, thereby minimizing the development of metastatic disease and allowing the ability to tailor therapeutic intervention. Objective: The present study aimed to examine whether the prostate cancer, and benign prostatic hyperplasia (BPH) patients have distinctive IL-18 and capsase 9 single nucleotide polymorphism (SNP) that could have an effect on disease susceptibility. Material and Methods: A case control study has been steered to attain this goal which is based on three groups include 50 patients with PCa (group 1), 50 patients with BHP (group 2) and 50 healthy (non BHP & non prostate) volunteers (group 3, control). Patients were under observation in the Thi Qar Oncology Center from the period of January 2018 till February 2019. Moreover, the supervision of specialists of oncology was also incorporated in this research. For the extraction of DNA, 2mL blood was directly collected to the EDTA comprising sterile tube. Then, amplification refractory mutation-PCR system (ARMS-PCR) technique is used to study interleukin-18 (IL-18) and caspase 9 polymorphism. Results: there was no significant difference among the BHP patient’s mean age and patients with prostatic cancer (P=0.093; 60.04±10.47 vs. 63.04±8.35 years, respectively); however, patients in both BPH and cancer groups were found to be significantly older as compared to the subjects of control group (P<0.001). IL-18 genotypes homozygous CC and heterozygous GC genotypes were significantly more frequent in patients with prostatic carcinoma in comparison with control group (P=0.002) and in comparison with BPH group (P=0.030). Caspase genotypes homozygous GG and heterozygous AG genotypes were significantly more frequent in patients with prostatic carcinoma in comparison with control group (P=0.003) and in comparison with BPH group (P=0.018); however, there was no significant difference in caspase 9 genotype frequency distribution between control and BPH groups (P=0.842). Conclusions: We can speculate that population who have AC, CC genotype for IL-18, and AG, GG genotype for caspase 9 could be at risk for malignant tumor formation, and this could emerging an approach which has the potential to improve prediction of susceptibility to prostate cancer and disease progression.


  • American Cancer Society: Cancer Facts & Figures (2003) Atlanta, GA: American Cancer Society.
  • Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132: 474e9.
  • Carter HB, Piantadosi S, Isaacs JT (1990) Clinical evidence for and implications of the multistep development of prostate cancer, J Urol143: 742–746.
  • Christudoss P, Selvakumar R, Fleming JJ, Gopalakrishnan G (2011) Zinc status of patients with benign prostatic hyperplasia and prostate carcinoma. Indian J Urol 27: 14-8
  • Crawford E David (2003) Epidemiology of Prostate Cancer. Urology; 62, December 22.
  • Deng B, Liu F, Luo L, Wei Y, Li B, Yang H (2016) CASP 3 genetic polymorphisms and risk of Hepatocellular carcinoma: a casecontrol study in a Chinese population.Tumour Biol 37(7): 8985-8991.
  • Giedraitis V, He B, Huang WX and Hillert J (2001) Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J. Neuroimmunol 112: 146-152.
  • Giedraitis V, He B, Huang WX, Hillert J (2001) Cloning and mutation analysis of the human IL-18 promoter: A possible role of polymorphisms in expression regulation. J Neuroimmunol 112: 14652.
  • Golab J (2000) Interleukin 18interferon gamma inducing factora novel player in tumour immunotherapy? Cytokine 12: 3328.
  • Haas GP, Sakr WA (1997) Epidemiology of prostate cancer. CA Cancer J Clin 47: 273–287.
  • Jang JS, Kim KM, Choi JE, Cha SI, Kim CH, Lee WK, Kam S (2008) Identification of polymorphisms in the Caspase‐3 gene and their association with lung cancer risk. Mol Carcinog 47(5): 383-390.
  • Kok Bin Lim (2017) Epidemiology of clinical benign prostatic hyperplasia. Asian Journal of Urology 4: 148e151.
  • Liu JM, Liu JN, Wei MT, He YZ, Zhou Y, Song XB, ... Huang J (2013) Effect of IL-18 gene promoter polymorphisms on prostate cancer occurrence and prognosis in Han Chinese population. Genet Mol Res 12(1): 820-829.
  • Loeb S, Kettermann A (2009) Carter HB, Ferrucci L, Metter EJ, Walsh PC. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol 182: 1458e62.
  • Mittal RD, Mittal T, Singh AK, Mandal RK (2012) Association of caspases with an increased prostate cancer risk in north Indian population. DNA Cell Biol 31(1): 67-73.
  • Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12: 5372.
  • Sarwar S, Adil MAM, Nyamath P, Ishaq M (2017) Biomarkers of prostatic cancer: an attempt to categorize patients into prostatic carcinoma, benign prostatic hyperplasia, or prostatitis based on serum prostate specific antigen, prostatic acid phosphatase, calcium, and phosphorus. Prostate Cancer.
  • Shokrzadeh M, Mohammadpour A, Masoudi N, Nasirian Shakib MM, Mohammadi SM, Saleh Tabari Y, Alizadeh M (2017) Association of rs12108497 (caspase 3 gene) polymorphism in gastric cancer patients in Sari. Journal of Genetic Resources 3(2): 98-102.
  • Sicramaz H, Ayar A, Ayar EN (2016) The evaluation of some dietary fiber rich by-products in ice creams made from the traditional pudding–kesme muhallebi. Journal of Food Technology, 3(2): 105-109.
  • Wu Z, Li Y, Li S, Zhu L, Li G, Yu Z, Zhao X (2013) Association between main Caspase gene polymorphisms and the susceptibility and prognosis of colorectal cancer. Med Oncol 30(3): 565.
  • Yan S, Li YZ, Zhu XW, Liu CL, Wang P, Liu YL (2013) HuGE systematic review and metaanalysis demonstrate association of CASP-3 and CASP-7 genetic polymorphisms with cancer risk. Genet Mol Res 12(2): 1561-1573.
  • Yoo SS, Choi JE, Lee WK, Choi YY, Kam S, Kim MJ, Jeon HS (2009) Polymorphisms in the CASPASE genes and survival in patients with early-stage non– small-cell lung cancer. J Clin Oncol 27(34): 5823-5829.
  • Zhou W, Chen Z, Hu W, Shen M (2011) Association of short tandem repeat polymorphism in the promoter of prostate cancer antigen 3 gene with the risk of prostate cancer. PLoS One: e20378.


This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.